Selected by Global Manufacturer as its Preferred Monitoring Solution for 3D Metal Printers & Presented as PrintRite3D Ready
Management to Host Conference Call Today at 4:30 p.m. ET
SANTA FE, NM / ACCESSWIRE / July 23, 2020 / Sigma Labs, Inc. (NASDAQ:SGLB) ("Sigma Labs"), a leading developer of quality assurance software for the additive manufacturing industry, reported its financial and operational results for the second quarter ended June 30, 2020.
Key Second Quarter 2020 and Subsequent Operational Highlights
- Selected by global manufacturer as its Preferred Monitoring Solution for 3D Metal Printers:
- Partnership will provide major 3D printer manufacturer's global customer base with industry leading 3rd party IPQA® (In-process Quality Assurance) solution for its line of 3D printers. The manufacturer will present their printers as PrintRite3D® ready;
- PrintRite3D will be actively promoted by a worldwide salesforce as their preferred monitoring solution; and
- Initial purchase orders expected in the third quarter of 2020.
- Launched @Sigma RTE program to provide potential end users and OEM's with a fast and inexpensive way to experience the benefits of Sigma's PrintRite3D IPQA® solution. Manufacturers worldwide will be able to experience using PrintRite3D® in real-time with their part design and chosen metal powder. Allows end users and global OEMs an opportunity to:
- Experience in-process quality assurance and melt pool analytics in action;
- Utilize Sigma's technology to improve build efficiency;
- Learn how PrintRite3D can help ensure consistency and solve quality issue; and
- Reduce product development time from initial design and simulation to production.
- Secured Japanese Fortune Global 50 manufacturer as its first customer under the @Sigma RTE program with new purchase order for PrintRite3D.
- Collaborated with NIST to outline how to calibrate PrintRite3D sensors to a traceable temperature standard.
- Performed a first ever standards calibration with the renowned National Institute of Standards and Technology;
- Opens the door for machine to machine calibration and enables machine matching for the Additive Manufacturing industry; and
- Represents a major milestone to ensuring quality in production environments.
- Appointed Mark K. Ruport as President and Chief Executive Officer, from his prior position as Executive Chairman, to further drive formation of strategic relationships, growth and sales strategies as the company commercializes its proprietary PrintRite3D technology. John Rice remains non-executive Chairman of the Board and has entered into a consulting contract with the company.
- Fortified the balance sheet with $1.5 million in gross proceeds through an April 2020 offering of common stock and warrants, and $1.64 million in gross proceeds from the exercise of preferred warrants.
Management Commentary
"The second quarter of 2020 marks the continuation of the Company's strategic plan - Increasing sales of PrintRite3D, driven by multiple independent revenue streams with exciting progress being made on potential breakthrough contracts at the hardware OEM level," said Mark K. Ruport, President and Chief Executive Officer of Sigma Labs. "Thanks to our new @Sigma RTE program, we secured a Fortune Global 50 manufacturer at significantly lower cost of sales than previously possible. This new initiative shortens our sales cycle, is asset light and allows OEMs and end users to experience using our IPQA® system to improve build efficiency and ensure quality. Moreover, this initiative is an example of how Sigma adapted to the new COVID world and worked with our agent in Japan to bring a new customer to our testing lab without anyone leaving their respective office. We look forward to new announcements in the weeks to come on this front.
"Our customers are increasingly engaged with our sales staff, reaffirming what we always knew to be true - that the market momentum and increased demand for more agile manufacturing systems due to COVID has been an exciting tailwind for Sigma and our increasingly plug-and-play PrintRite3D product.
"On the financial front, our $1.5 million offering in April 2020 has served to fortify our balance sheet against market uncertainty resulting from the COVID-19 pandemic and subsequent macro-economic pressure. This, paired with a reduction in cash burn by over $100,000 per month, has better positioned us to weather any macro-economic storms that may arise over the coming months. Executive salary deferments and other cuts such as these stand as a testament to our team's belief in the long-term potential of our product and our commitment to create value for our shareholders.
"Over the coming months, I will continue to focus my efforts on four main areas: Increasing quarter-over quarter revenue driven by multiple independent revenue streams; driving multi-unit sales of PrintRite3D Production Series by end users that have validated our technology through the @Sigma RTE program; forming new strategic alliances and OEM contracts with both additive manufacturing hardware and software companies that provide sales leverage and market validation; and continued success with R&D organizations and Universities with advanced manufacturing programs, training tomorrow's manufacturing leaders on the value of a 3rd party, standards-based IPQA® solution for 3D printing.
"As evidenced by these new wins, the customer evolution has migrated from R&D to End Users to now OEMs. I believe that we are on the cusp of the industrialization of 3D metal printing and PrintRite3D is positioned as a critical component, or the missing link, in Additive Manufacturing's digital chain. Today, we have initiatives in India, Japan, throughout Europe and in countries like Turkey, all accelerating their adoption of AM to lessen their dependency on other countries and increasing their ability to be self-sufficient in times of crisis.
"The macro backdrop for additive manufacturing has never been stronger and Sigma is now uniquely positioned to set the standard for quality assurance for Additive Manufacturing. Despite the COVID crisis, we have strengthened our balance sheet, preserved our cash and added additional sales and marketing resources, positioning the company for strong growth as the economy improves. We look forward to sharing more on our developing story at upcoming virtual events in the third quarter," concluded Ruport.
Second Quarter 2020 Financial Results
Revenue for the second quarter of 2020 totaled $0.2 million. This compares to revenues of $34 thousand for the second quarter of 2019. The increase in revenue was due to a PrintRite3D® unit sale, as well as revenue recognized under the legacy Rapid Test and Evaluation ("RTE") program and an in-house RTE during the quarter.
Gross profit for the second quarter of 2020 was $0.1 million as compared to negative $27 thousand in the second quarter of 2019.
Total operating expenses for the second quarter of 2020 were $1.53 million as compared to total operating expenses of $1.57 million for the same period in 2019.
Cash used in operating activities for the six months ended June 30, 2020 totaled $2.4 million compared to $2.7 million in the first six months ended June 20, 2019. Approximately $400 thousand of this amount was due to trade accounts payables carried over from 2019 due to a delay in financing.
Net loss for the second quarter of 2020 was $1.6 million, or $(0.49) per share, as compared to a net loss of $1.6 million, or $(1.50) per share, in the second quarter of 2019.
Cash totaled $2.5 million at June 30, 2020, as compared to $0.6 million at March 31, 2020 and $0.6 million at June 30, 2019.
Second Quarter 2020 Results Conference Call
Sigma Labs President and CEO Mark Ruport and CFO Frank Orzechowski will host the conference call, followed by a question and answer period.
To access the call, please use the following information:
Date: | Thursday, July 23, 2020 |
Time: | 4:30 p.m. Eastern time, 1:30 p.m. Pacific time |
Toll-free dial-in number: | 1-877-407-9039 |
International dial-in number: | 1-201-689-8470 |
Conference ID: | 13706559 |
Please call the conference telephone number 5-10 minutes prior to the start time. An operator will register your name and organization. If you have any difficulty connecting with the conference call, please contact MZ Group at 1-949-491-8235.
The conference call will be broadcast live and available for replay at http://public.viavid.com/index.php?id=140600 and via the investor relations section of the Company's website at www.sigmalabsinc.com.
A replay of the conference call will be available after 7:30 p.m. Eastern time through August 6, 2020.
Toll-free replay number: | 1-844-512-2921 |
International replay number: | 1-412-317-6671 |
Replay ID: | 13706559 |
About Sigma Labs
Sigma Labs Inc. (NASDAQ: SGLB) is a leading provider of quality assurance software to the commercial 3D metal printing industry under the PrintRite3D® brand. Sigma specializes in the development and commercialization of real-time monitoring solutions known as PrintRite3D® for 3D metal advanced manufacturing technologies. PrintRite3D detects and classifies defects and anomalies real-time during the manufacturing process and informs the production manager of quality issues. Sigma Labs' software product is a major catalyst for the acceleration and adoption of 3D metal printing. For more information, please visit www.sigmalabsinc.com.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words "believe," "anticipate," "estimate," "expect," "intend," "plan," "project," "prospects," "outlook," and similar words or expressions, or future or conditional verbs such as "will," "should," "would," "may," and "could" are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors, including, but not limited to, the uncertain effect of the COVID-19 pandemic on the Company's business, results of operations and financial condition, which may cause the Company's actual results, performance or achievements to be materially different from any anticipated results, performance or achievements. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K (including but not limited to the discussion under "Risk Factors" therein) filed with the SEC on March 24, 2020 and which may be viewed at www.sec.gov.
Investor Contact:
Chris Tyson
Managing Director
MZ Group - MZ North America
949-491-8235
SGLB@mzgroup.us
www.mzgroup.us
Company Contact:
Steven Gersten
Sigma Internal IR
investors@sigmalabsinc.com
Sigma Labs, Inc.
Condensed Balance Sheets
(Unaudited)
| June 30, 2020 | December 31, 2019 | |||||||
ASSETS | ||||||||
Current Assets: | ||||||||
Cash | $ | 2,445,766 | $ | 86,919 | ||||
Accounts Receivable, net | 286,405 | 55,540 | ||||||
Inventory | 585,640 | 598,718 | ||||||
Prepaid Assets | 118,031 | 199,727 | ||||||
Total Current Assets | 3,435,842 | 940,904 | ||||||
Other Assets: | ||||||||
Property and Equipment, net | 117,006 | 128,723 | ||||||
Intangible Assets, net | 644,286 | 569,341 | ||||||
Investment in Joint Venture | - | 500 | ||||||
Long-Term Prepaid Asset | 52,000 | 52,000 | ||||||
Total Other Assets | 813,292 | 750,564 | ||||||
TOTAL ASSETS | $ | 4,249,134 | $ | 1,691,468 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current Liabilities: | ||||||||
Accounts Payable | $ | 295,220 | $ | 727,114 | ||||
Notes Payable | - | 50,000 | ||||||
Deferred Revenue | 99,588 | 139,447 | ||||||
Accrued Expenses | 272,442 | 122,658 | ||||||
Total Current Liabilities | 667,250 | 1,039,219 | ||||||
Long-Term Liabilities: | ||||||||
CARES Act Deferred Payroll Tax Liability | 22,072 | - | ||||||
Total Long-Term Liabilities | 22,072 | - | ||||||
TOTAL LIABILITIES | 689,322 | 1,039,219 | ||||||
Stockholders' Equity | ||||||||
Preferred Stock, $0.001 par; 10,000,000 shares authorized; 333 and 0 issued and outstanding, respectively | 1 | - | ||||||
Common Stock, $0.001 par; 12,000,000 shares authorized; 3,926,362 and 1,403,759 issued and outstanding, respectively | 3,926 | 1,404 | ||||||
Additional Paid-In Capital | 33,151,829 | 26,746,439 | ||||||
Accumulated Deficit | (29,595,944 | ) | (26,095,594 | ) | ||||
Total Stockholders' Equity | 3,559,812 | 652,249 | ||||||
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 4,249,134 | $ | 1,691,468 | ||||
Sigma Labs, Inc.
Condensed Statements of Operations
(Unaudited)
| Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||||
| 2020 | 2019 | 2020 | 2019 | |||||||||||||
REVENUES | $ | 167,688 | $ | 33,582 | $ | 389,418 | $ | 98,032 | ||||||||
COST OF REVENUE | 57,684 | 60,625 | 302,387 | 157,180 | ||||||||||||
GROSS PROFIT (LOSS) | 110,004 | (27,043) | 87,031 | (59,148) | ||||||||||||
OPERATING EXPENSES: | ||||||||||||||||
Salaries & Benefits | 605,295 | 581,356 | 1,257,492 | 1,093,916 | ||||||||||||
Stock-Based Compensation | 270,818 | 220,360 | 424,989 | 474,566 | ||||||||||||
Operating R&D Costs | 111,647 | 118,845 | 165,335 | 264,117 | ||||||||||||
Investor & Public Relations | 171,287 | 157,318 | 409,555 | 315,107 | ||||||||||||
Legal & Professional Service Fees | 219,007 | 218,919 | 430,515 | 403,489 | ||||||||||||
Office Expenses | 78,843 | 184,068 | 226,590 | 350,178 | ||||||||||||
Depreciation & Amortization | 17,970 | 49,203 | 35,983 | 97,586 | ||||||||||||
Other Operating Expenses | 51,687 | 38,994 | 135,736 | 77,203 | ||||||||||||
Total Operating Expenses | 1,526,554 | 1,569,064 | 3,086,195 | 3,076,162 | ||||||||||||
LOSS FROM OPERATIONS | (1,416,550 | ) | (1,596,107 | ) | (2,999,164 | ) | (3,135,310 | ) | ||||||||
OTHER INCOME (EXPENSE) | ||||||||||||||||
Interest Income | 31 | 7,016 | 882 | 12,798 | ||||||||||||
State Incentives | 151,657 | - | 151,657 | 51,877 | ||||||||||||
Exchange Rate Gain (Loss) | (31 | ) | (2,264 | ) | (1,422 | ) | (2,710 | ) | ||||||||
Interest Expense | (6,244 | ) | (2,136 | ) | (6,675 | ) | (4,258 | ) | ||||||||
Loss on Dissolution of Joint Venture | (201 | ) | - | (201 | ) | |||||||||||
Other Income | 361,700 | - | 361,700 | - | ||||||||||||
Total Other Income (Expense) | 506,912 | 2,616 | 505,941 | 57,707 | ||||||||||||
LOSS BEFORE PROVISION FOR INCOME TAXES | (909,638) | (1,593,491) | (2,493,223) | (3,077,603) | ||||||||||||
Provision for income Taxes | - | - | - | - | ||||||||||||
Net Loss | $ | (909,638) | $ | (1,593,491) | $ | (2,493,223) | $ | (3,077,603) | ||||||||
Preferred Dividends | (691,880 | ) | - | (1,007,127 | ) | - | ||||||||||
Net Loss Applicable to Common Stockholders | $ | (1,601,518) | $ | (1,593,491) | $ | (3,500,350) | $ | (3,077,603) | ||||||||
Net Loss per Common Share - Basic and Diluted | $ | (0.49) | $ | (1.50) | $ | (1.48) | $ | (3.10) | ||||||||
Weighted Average Number of Shares Outstanding - Basic and Diluted | 3,256,098 | 1,077,759 | 2,359,862 | 1,006,381 | ||||||||||||
Sigma Labs, Inc.
Condensed Statements of Cash Flows
(Unaudited)
| Six Months Ended | ||||||||
| June 30, 2020 | June 30, 2019 | |||||||
OPERATING ACTIVITIES | ||||||||
Net Loss | $ | (2,493,223 | ) | $ | (3,077,603 | ) | ||
Adjustments to reconcile Net Loss to Net Cash used in operating activities: | ||||||||
Noncash Expenses: | ||||||||
Depreciation and Amortization | 35,983 | 97,586 | ||||||
Stock Based Compensation | 424,989 | 474,150 | ||||||
Securities Issued for Third Party Services | 54,924 | - | ||||||
Change in assets and liabilities: | ||||||||
Accounts Receivable | (230,865 | ) | 818 | |||||
Interest Receivable | - | 27,038 | ||||||
Inventory | 13,078 | (330,340 | ) | |||||
Prepaid Assets | 81,695 | (1,463 | ) | |||||
Accounts Payable | (431,893 | ) | 150,567 | |||||
Deferred Revenue | (39,860 | ) | 27,275 | |||||
Accrued Expenses | 149,785 | (105,678 | ) | |||||
NET CASH USED IN OPERATING ACTIVITIES | (2,435,387 | ) | (2,737,650) | |||||
INVESTING ACTIVITIES | ||||||||
Purchase of Property and Equipment | (11,474 | ) | (23,796 | ) | ||||
Purchase of Intangible Assets | (87,736 | ) | (107,124 | ) | ||||
Payment Received from Notes Receivable | - | 15,000 | ||||||
Dissolution of Joint Venture | 500 | - | ||||||
NET CASH USED IN INVESTING ACTIVITIES | (98,710 | ) | (115,920) | |||||
FINANCING ACTIVITIES | ||||||||
Gross Proceeds from Public and Private Issuances of Securities | 3,600,000 | 2,521,220 | ||||||
Less Offering Costs | (820,228 | ) | (326,890 | ) | ||||
Payment of Note Payable | (50,000 | ) | - | |||||
Proceeds from Exercise of Warrants | 2,141,100 | 75,848 | ||||||
Deferral of Payroll Taxes under the CARES Act | 22,072 | - | ||||||
NET CASH PROVIDED BY FINANCING ACTIVITIES | 4,892,944 | 2,270,178 | ||||||
NET CHANGE IN CASH FOR PERIOD | 2,358,847 | (583,392) | ||||||
CASH AT BEGINNING OF PERIOD | 86,919 | 1,279,782 | ||||||
CASH AT END OF PERIOD | $ | 2,445,766 | $ | 696,390 | ||||
Supplemental Disclosures: | ||||||||
Noncash investing and financing activities disclosure: | ||||||||
Issuance of Common Shares for Conversion of Preferred Shares and Preferred Dividends | $ | 3,417,967 | $ | - | ||||
Issuance of Securities for services | $ | 62,794 | $ | 153,000 | ||||
Disclosure of cash paid for: | ||||||||
Interest | $ | 9,359 | $ | 2,514 | ||||
Income Taxes | $ | - | $ | - | ||||
SOURCE: Sigma Labs, Inc.
View source version on accesswire.com:
https://www.accesswire.com/598648/Sigma-Labs-Reports-Second-Quarter-2020-Financial-Results
